Talazoparib in Patients With Solid Tumors With BRCA1 / 2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.
Gordan SrkalovicMichael RothePam K MangatElizabeth Garrett-MayerEugene R AhnGregory BrouseJohn ChanInderjit MehmiMaya KhalilHerbert L DuvivierAnu GabaHarshraj LeuvaRamya ThotaKathleen J YostGina N GranthamAbigail GregoryDominique C HinshawSusan HalabiRichard L SchilskyPublished in: JCO precision oncology (2024)
mutations, including cancer types for which poly ADP-ribose polymerase inhibitors are not yet US Food and Drug Administration-approved.